Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: review of Technology Appraisal 33
National Institute for Clinical Excellence
Record ID 32005001170
English
Authors' objectives:
This guidance replaces Technology Appraisal Guidance No. 33 issued in March 2002. The Institute reviews each piece of guidance it issues. The review and re-appraisal of the use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer has resulted in a change in the guidance.
Authors' recommendations:
Guidance
1.1 Irinotecan and oxaliplatin, within their licensed indications, are recommended as treatment options for people with advanced colorectal cancer as follows: - irinotecan in combination with 5-fluorouracil and folinic acid as first-line therapy, or irinotecan alone in subsequent therapy - oxaliplatin in combination with 5-fluorouracil and folinic acid as first-line or subsequent therapy.
1.2 Raltitrexed is not recommended for the treatment of patients with advanced colorectal cancer. Its use for this patient group should be confined to appropriately designed clinical studies.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.nice.org.uk/page.aspx?o=268582
Year Published:
2005
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antineoplastic Agents
- Colorectal Neoplasms
Contact
Organisation Name:
National Institute for Clinical Excellence
Contact Address:
MidCity Place, 71 High Holborn, London WC1V 6NA, UK. Tel: +44 020 7067 5800; Fax: +44 020 7067 5801
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.